2025-08-20 - Analysis Report
Okay, here's an analysis of Procter & Gamble (PG) based on the data provided, presented in a structured report format with key numbers and accompanying analysis.

**Report: Procter & Gamble Co (PG) Analysis**

**0. Executive Summary**

This report analyzes Procter & Gamble Co. (PG), a global consumer goods company, based on recent performance metrics, market indicators, news events, and financial data. The analysis covers relative performance against the S&P 500 (VOO), recent price trends, risk indicators, earnings, and financial health.  The report concludes with an overall assessment of PG's current standing and potential outlook.

**1. Relative Performance & Alpha/Beta Analysis**

*   **Company Overview:** Procter & Gamble Co (PG) is a global consumer goods company providing a wide range of branded products.
*   **PG Cumulative Return:** 44.71%
*   **VOO (S&P 500) Cumulative Return:** 100.85%
*   **Relative Deviation (Tracking Error):**
    *   Max: 36.1
    *   Min: -46.4
    *   Current: -46.4
    *   Relative Deviation Percentile: 0.0

**Analysis:** PG has significantly underperformed the S&P 500 over the analyzed period. The current deviation is at the lowest end of its historical range, indicating substantial underperformance relative to the benchmark. The Relative Deviation Percentile of 0 suggests that PG's underperformance is at the lower extreme of its historical distribution compared to the S&P 500.

*   **Alpha/Beta Metrics:**

| Year       | CAGR   | MDD     | Alpha   | Beta  | Cap(B) |
|------------|--------|---------|---------|-------|--------|
| 2015-2017  | 21.0% | 7.9%  | -8.0%   | 0.0   | 218.9  |
| 2016-2018  | 5.0%  | 56.7% | -13.0%  | 0.1   | 219.0  |
| 2017-2019  | 30.0% | 56.7% | 0.0%    | 0.5   | 297.6  |
| 2018-2020  | 38.0% | 59.1% | 18.0%   | 0.3   | 331.5  |
| 2019-2021  | 56.0% | 59.1% | 8.0%    | 0.3   | 389.8  |
| 2020-2022  | 24.0% | 74.7% | 22.0%   | 0.3   | 361.1  |
| 2021-2023  | 30.0% | 74.7% | 12.0%   | 0.3   | 349.2  |
| 2022-2024  | 8.0%  | 74.7% | -17.0%  | 0.3   | 399.5  |
| 2023-2025  | -15.0% | 71.6% | -68.0%  | 0.2   | 371.0  |

**Analysis:**

*   **Alpha:** Alpha is generally negative, especially in recent periods (e.g., -68.0% for 2023-2025), indicating underperformance compared to its benchmark.
*   **Beta:** Beta values are low (mostly around 0.3 or lower), suggesting that PG's price is not strongly correlated with the overall market. This implies that PG is relatively less volatile than the market.
*   **CAGR:** The Compound Annual Growth Rate (CAGR) has declined and turned negative recently (-15.0% for 2023-2025), signaling a decrease in overall performance.
*   **MDD:** The Maximum Drawdown (MDD) is high across the board, indicating significant potential losses from peak to trough during these periods.

**2. Recent Price Volatility**

*   **Current Price:** 155.72
*   **Last Market Data:**
    *   Price: 158.4
    *   Previous Close: 155.72
    *   Change: 1.72
*   **Moving Averages:**
    *   5-day MA: 154.86
    *   20-day MA: 154.59
    *   60-day MA: 158.83

**Analysis:** The current price is above the 5-day and 20-day moving averages, suggesting short-term upward momentum. However, it is below the 60-day moving average, indicating potential resistance in the medium term. The last market data shows a positive change (1.72), indicating a recent upward trend.

**3. Risk and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.329 (Low Risk)
*   **RSI:** 47.08
*   **PPO:** 0.2993
*   **Hybrid Signal:** Buy 90% of cash (1 shares - Safe - MRI:0.33)
*   **Recent (20-day) Relative Deviation Change:** -0.8 (Negative – indicating a short-term decline)
*   **Expected Return (%):** 1490.8 (Projected excess return over S&P 500 with long-term investment)

**Analysis:**

*   The MRI indicates low market risk.
*   The RSI of 47.08 suggests a neutral condition (not overbought or oversold).
*   The PPO of 0.2993 implies slight upward momentum but is relatively low.
*   The Hybrid Signal suggests a strong buy recommendation.
*   The negative change in relative deviation indicates recent underperformance.
*   The significantly high expected return (1490.8%) should be viewed with caution, as it is likely an optimistic projection based on the model.

The price change {'price': 158.4, 'previousClose': 155.72, 'change': 1.72} indicates a recent rebound, which should be considered in light of the other indicators.

**4. Recent News & Significant Events**

*   **2025-08-20:** Procter & Gamble Co (PG) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-08-17:** Analysts are discussing Procter & Gamble Co's (PG) recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-08-18:** Procter & Gamble Co (PG)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-08-19:** Market experts highlight both risks and opportunities for Procter & Gamble Co (PG), advising investors to monitor recent news and company announcements.

**Analysis:** Recent news indicates volatility and discussions around PG's performance. Monitoring specific company announcements and news developments is crucial for assessing the company's near-term trajectory.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출      |
|--------------|-------|-----------|
| 2025-04-24   | 1.58  | 19.78 B$  |
| 2025-01-22   | 1.94  | 21.88 B$  |
| 2024-10-18   | 1.65  | 21.74 B$  |
| 2024-04-19   | 1.56  | 20.20 B$  |
| 2025-04-24   | 1.56  | 20.20 B$  |

**Analysis:**

*   **EPS:** The Earnings Per Share (EPS) values fluctuate between 1.56 and 1.94. There is no clear upward or downward trend in EPS across the reported quarters.
*   **Revenue:** The revenue values range from $19.78B to $21.88B. There is some variability in the revenue, but no consistent growth pattern is evident.

Overall, the earnings and revenue data indicate a stable but not rapidly growing performance for Procter & Gamble.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $20.89B    | 49.11%       |
| 2025-03-31   | $19.78B    | 50.98%       |
| 2024-12-31   | $21.88B    | 52.39%       |
| 2024-09-30   | $21.74B    | 52.06%       |
| 2024-06-30   | $20.53B    | 49.60%       |

**Capital and Profitability**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-06-30   | $52.01B    | 6.95% |
| 2025-03-31   | $52.27B    | 7.21% |
| 2024-12-31   | $51.17B    | 9.05% |
| 2024-09-30   | $51.84B    | 7.64% |
| 2024-06-30   | $50.29B    | 6.24% |

**Analysis:**

*   **Revenue and Profit Margin:** Revenue fluctuates, with the highest revenue in Q4 2024 ($21.88B). Profit margins are consistently high, around 50%.
*   **Capital and Profitability:** Equity remains relatively stable. Return on Equity (ROE) varies, with the highest ROE in Q4 2024 (9.05%), indicating the company's efficiency in generating profits from its equity.

**7. Overall Assessment**

Based on the provided data:

*   **Performance:** PG has underperformed the S&P 500 significantly, as reflected in the large negative deviation and negative alpha values. The recent CAGR is also negative, further supporting this trend.
*   **Valuation & Momentum:** The recent price increase and buy signal from the Hybrid Signal indicate a potential short-term recovery. However, the price remains below the 60-day moving average.
*   **Risk:** The MRI indicates low market risk, and PG exhibits low beta, suggesting lower volatility compared to the market.
*   **Financial Health:** PG maintains healthy profit margins and a stable equity base. The ROE varies but remains within a reasonable range, reflecting consistent profitability.
*   **News & Events:** The recent volatility and analyst discussions suggest that PG is undergoing changes or facing market pressures that require monitoring.

**Conclusion:**

PG is currently underperforming relative to the S&P 500, but its financial health remains stable with high profit margins and consistent profitability. The recent price increase and buy signal may suggest a short-term recovery. However, the long-term expected return should be viewed cautiously. Investors should closely monitor company announcements and market developments to assess PG's future trajectory.

I hope this report is comprehensive and helpful!
